Vobramitamab (CAS 2490556-50-6) is a humanized monoclonal antibody that targets B7-H3, a protein found on certain tumor cells. When conjugated with the prodrug seco-DUBA via a cleavable linker, it forms the antibody-drug conjugate (ADC) MGC018. This ADC helps inhibit tumor growth and enhances immune-mediated destruction of the tumor cells.
Key Features:
- Target Specificity: Binds to B7-H3 on tumor cells.
- Mechanism of Action: Inhibits tumor growth and boosts immune-mediated destruction.
- Molecular Characteristics: Humanized IgG1 monoclonal antibody conjugated with seco-DUBA.
Applications:
- Cancer Therapy: Investigated for treating solid tumors that overexpress B7-H3.
- Antibody-Drug Conjugates (ADCs): Used in MGC018 for targeted drug delivery.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
